Guardant’s Multi-Cancer Detection Test Granted FDA Breakthrough Device Designation
Guardant Health’s methylation-based blood test – Shield MCD – showed a specificity of 98.6% and sensitivity of 75% across eight cancer types in its clinical validation data presented at ASCO.